Lipocine Inc.
LPCN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001535955
In the last 90 days, Lipocine Inc. insiders filed 1 open-market purchase and 0 sales; 36 institutions reported holding it in 13F filings for Q2 2026, worth $7.63M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Lipocine Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 47 | 36 | −11 |
| Shares | 3.12M | 2.98M | −138.0K (−4.4%) |
| Value | $24.9M | $7.63M | −$17.3M (−69.4%) |
New holders (4)
Institutions that held Lipocine Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Acadian Asset Management LLC | 170,417 | $435.0K | 0.00% |
| HRT Financial LP | 29,238 | $74.0K | 0.00% |
| Gsa Capital Partners LLP | 18,666 | $48.0K | 0.00% |
| Price T Rowe Associates Inc | 12,266 | $32.0K | 0.00% |
Sold out (15)
Institutions that held Lipocine Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Rosalind Advisors, Inc. | 221,616 | $1.77M |
| AIGH Capital Management LLC | 200,000 | $1.60M |
| StemPoint Capital LP | 160,420 | $1.28M |
| Mink Brook Asset Management LLC | 66,812 | $533.8K |
| Exome Asset Management LLC | 60,861 | $486.3K |
| Diadema Partners LP | 50,000 | $399.5K |
| J. Goldman & Co LP | 42,170 | $336.9K |
| ADAR1 Capital Management, LLC | 23,180 | $185.2K |
| XTX Topco Ltd | 17,923 | $143.2K |
| Persistent Asset Partners Ltd | 13,442 | $107.4K |
| Prelude Capital Management, LLC | 12,630 | $100.9K |
| Ameriprise Financial Inc | 11,448 | $91.5K |
| FMR LLC | 626 | $5.00K |
| JPMorgan Chase & Co | 392 | $2.97K |
| Royal Bank of Canada | 50 | $0 |